Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIMP3 | P35625 | 2/20 | 0.56 |
| ▸ | TOP1 | P11387 | 2/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31520127 | 0.89 | MDM4 (0.56) | CA1CA2MEN1KMT2ARAB9A | |
| SCHEMBL2893166 | 0.89 | MDM4 (0.56) | CA1CA2MEN1KMT2ARAB9A | |
| SCHEMBL6244552 | 0.83 | CD40 (0.49) | TIMP3TOP1TOP2ATOP2BMEN1 | |
| SCHEMBL15922175 | 0.83 | CA1 (0.57) | CA1CA2MEN1KMT2ARAB9A | |
| SCHEMBL11831116 | 0.83 | SMN1; SMN2 (0.57) | CA1CA2MEN1KMT2ARAB9A | |
| SCHEMBL6242038 | 0.82 | CD40 (0.61) | TIMP3TOP1TOP2ATOP2BMEN1 | |
| SCHEMBL31520132 | 0.81 | CA1 (0.55) | CA1CA2KMT2ARAB9APKM | |
| SCHEMBL10893116 | 0.81 | CA2 (0.54) | TIMP3CA1CA2MEN1KMT2A | |
| SCHEMBL6242899 | 0.80 | CCR8 (0.58) | TIMP3TOP1TOP2ATOP2BMEN1 | |
| SCHEMBL12669228 | 0.80 | CA1 (0.50) | TIMP3CA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315695-A2 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | Telik, Inc. (US) | 2003-06-04 | — | — | EP | claimed |
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | TELIK, INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002020464-A2 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | TELIK, INC. (US) | 2002-03-14 | — | — | WO | claimed |
| EP-1315695-B1 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | TELIK INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6600069-B2 | Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example | TELIK, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | TELIK, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | GPR119, INSR, IRS1 | TIMP3 4177/4885TOP1 2980/4885TOP2A 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.